Autistic disorder therapeutics market set to grow to $5.5 billion by 2018

The autism spectrum disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 7.5% over the next eight years to reach $5.5 billion by 2018, finds GlobalData’s new report titled Autistic Disorder Therapeutics.

This market growth is primarily attributed to the high prevalence (0.6% to 1%) and prevalence growth rate (10-17%) of ASD in the US and in certain European countries. Co-morbidities such as anxiety, epilepsy and depression associated with ASD also contribute to the growth of the ASD therapeutics market.

The current competitive landscape consists of two approved drugs, Bristol-Myers Squibb and Otsuka’s Abilify (aripiprazole) and risperidone, for the treatment of irritability associated with autistic disorder; and psychotropic medications such as anti-psychotics, anti-depressants, anti-convulsants and stimulants which are prescribed off-label.